PCSK9 and cardiovascular disorder: Inclisiran, a small interfering RNA therapy targeting PCSK9 synthesis, significantly reduced LDL cholesterol levels in patients with atherosclerotic cardiovascular disease or risk equivalents, showing sustained LDL reductions with an infrequent dosing schedule (every six months). The treatment was well tolerated with a safety profile similar to placebo.